A detailed history of Teacher Retirement System Of Texas transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Teacher Retirement System Of Texas holds 11,684 shares of ZNTL stock, worth $38,790. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,684
Previous 11,028 5.95%
Holding current value
$38,790
Previous $174,000 72.41%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$4.09 - $16.13 $2,683 - $10,581
656 Added 5.95%
11,684 $48,000
Q1 2024

May 06, 2024

SELL
$10.83 - $16.49 $4,299 - $6,546
-397 Reduced 3.47%
11,028 $174,000
Q4 2023

Feb 07, 2024

SELL
$9.84 - $20.13 $25,465 - $52,096
-2,588 Reduced 18.47%
11,425 $173,000
Q3 2023

Oct 31, 2023

SELL
$19.63 - $28.29 $24,439 - $35,221
-1,245 Reduced 8.16%
14,013 $281,000
Q2 2023

Jul 19, 2023

BUY
$17.41 - $30.05 $20,770 - $35,849
1,193 Added 8.48%
15,258 $430,000
Q1 2023

May 12, 2023

BUY
$16.14 - $24.94 $5,616 - $8,679
348 Added 2.54%
14,065 $242,000
Q4 2022

Feb 10, 2023

SELL
$18.07 - $25.6 $21,268 - $30,131
-1,177 Reduced 7.9%
13,717 $276,000
Q3 2022

Nov 03, 2022

BUY
$20.23 - $31.73 $150,389 - $235,880
7,434 Added 99.65%
14,894 $323,000
Q2 2022

Aug 09, 2022

BUY
$17.91 - $52.25 $49,986 - $145,829
2,791 Added 59.78%
7,460 $210,000
Q1 2022

May 09, 2022

BUY
$41.58 - $80.89 $14,386 - $27,987
346 Added 8.0%
4,669 $215,000
Q4 2021

Feb 10, 2022

BUY
$66.92 - $84.79 $71,002 - $89,962
1,061 Added 32.53%
4,323 $363,000
Q3 2021

Nov 09, 2021

BUY
$46.83 - $73.5 $152,759 - $239,757
3,262 New
3,262 $217,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $189M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Teacher Retirement System Of Texas Portfolio

Follow Teacher Retirement System Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teacher Retirement System Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on Teacher Retirement System Of Texas with notifications on news.